Full Press Release Details
Innate Pharma announces conference call and webcast for full year 2025 financial results
Marseille, France, March 19, 2026, 7 00 AM CET
Innate Pharma SA (Euronext Paris IPH Nasdaq IPHA) ("Innate" or the "Company"), today announces that the Company will hold a conference call on Thursday, March 26, 2026 at 2 p.m. CET 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2025.
Participants during the call will be
Jonathan Dickinson, Chief Executive Officer
Sonia Quaratino, Executive Vice President, Chief Medical Officer
Yannis Morel, Executive Vice President, Chief Operating Officer
St phanie Cornen, Vice President, Investor Relations, Communication and Commercial Strategy
Fr d ric Lombard, Senior Vice President, Chief Financial Officer
Details for the Virtual Event
The live webcast will be available at the following link
https events.q4inc.com attendee 704730270
Participants may also join via telephone using the following registration link https events.q4inc.com analyst 704730270 pwd usHLLD39
This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company website for 90 days following the event.
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.
Innate Pharma is advancing a portfolio of differentiated potential first and or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.
Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.
Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Information about Innate Pharma shares
ISIN code FR0010331421
Ticker code Euronext IPH Nasdaq IPHA
LEI 9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk factors
For a discussion of risks and uncertainties, please refer to the Risk Factors ("Facteurs de Risque ) section of the Universal Registration Document filed with the French Financial Markets Authority ("AMF"), which is available on the AMF website http www.amf-france.org or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 20-F for the year ended December 31,
2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
For additional information, please contact
Investors Media Relations
stephanie.cornen innate-pharma.fr
investors innate-pharma.fr
communication innate-pharma.fr